Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

P. M. Ridker*, J. Revkin, P. Amarenco, R. Brunell, M. Curto, F. Civeira, M. Flather, R. J. Glynn, J. Gregoire, J. W. Jukema, Y. Karpov, J. J. P. Kastelein, W. Koenig, A. Lorenzatti, P. Manga, U. Masiukiewicz, M. Miller, A. Mosterd, J. Murin, J. C. NicolauS. Nissen, P. Ponikowski, R. D. Santos, P. F. Schwartz, H. Soran, H. White, R. S. Wright, M. Vrablik, C. Yunis, C. L. Shear, SPIRE Cardiovascular Outcome Inve, Abraham Kroon, J. -C. Tardif

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1527-1539
Number of pages13
JournalNew England Journal of Medicine
Volume376
Issue number16
DOIs
Publication statusPublished - 20 Apr 2017

Keywords

  • STATIN THERAPY
  • GENETIC-VARIANTS
  • REDUCING LIPIDS
  • EVENTS
  • METAANALYSIS
  • PCSK9
  • REDUCTION
  • TRIALS

Cite this